FINWIRES · TerminalLIVE
FINWIRES

GrainCorp Cuts 80 Positions After Agribusiness Operating Model Review; Expects Higher Run-Rate Benefits From Business Transformation

By

GrainCorp (ASX:GNC) cut about 80 positions following a review of its agribusiness operating model, which identified opportunities to reduce duplication across the company's integrated East Coast of Australia network and corporate support functions, according to a Thursday filing with the Australian bourse.

The company incurred one-off restructuring costs of AU$5 million in fiscal 2026 related to the operating model changes, which are expected to improve execution and boost financial performance outcomes, per the filing.

Additionally, GrainCorp said its business transformation program is on track to deliver run-rate benefits of AU$12 million by the end of fiscal 2026, which is above the company's previously disclosed commitment.

The expected benefits build momentum toward a targeted uplift of AU$20 million to AU$30 million in through-the-cycle earnings before interest, taxes, depreciation, and amortization (EBITDA) by the end of fiscal 2028, the company said.

It is also pursuing a systems transformation, where late-stage testing has resulted in a decision to extend the deployment timeline. The first release under the transformation is now expected post-harvest in the second quarter of 2027, an extension from the previous target for the second half of this year.

GrainCorp now expects spend for the first release in fiscal 2027 to be between AU$30 million and AU$35 million to complete the program, representing an increase of $30 million.

The company reaffirmed its fiscal 2026 underlying EBITDA outlook at AU$200 million to AU$240 million, and underlying net profit after tax guidance at AU$20 million to AU$50 million.

Related Articles

Asia

Canadian Phosphate Confirms Nine Kilometers Strike Continuity at Canada Project

Canadian Phosphate (ASX:CP8) confirmed around 9 kilometers of strike continuity at its Wapiti Project in British Columbia, with drilling extending phosphate mineralization along the eastern limb of the Red Deer Syncline, according to a Wednesday filing with the Australian bourse.The company has completed 18 holes spanning 2,638 meters, with first assays expected in September, while exploration has shifted to the western limb, using historical drilling to guide new targets, per the filing.The company will increase funding and expand drilling beyond the previously planned 3,000 meters, supported by light detection and ranging, orthoimagery, mapping and sampling to enhance resource potential and geological confidence, the filing said.The company has deferred the Barnes bulk sample to the second quarter of 2027, opting instead to use about 30,000 tonnes of previously mined phosphate rock in Montana to meet near-term customer demand while redirecting funding to its Wapiti exploration program, the filing added.

ASX:CP8
Asia

Market Chatter: Posco Union Workers Start Two-Day Partial Strike Over Wage Dispute

Posco (KRX:005490) union workers began the first day of their two-day partial strike on Wednesday after negotiations with management over wages and other compensation failed in South Korea, Yonhap News reported the same day.Workers began a 48-hour partial strike, with 40 participating employees at the Pohang plant and 80 at the Gwangyang plant. The union is seeking a 7.1% base pay raise, a 600% performance bonus, 50 company shares per worker and a 200% holiday bonus, while management has proposed a 2% wage hike, the report said.The steelmaker expects negligible impact on production due to the lower worker participation and plans measures to prevent overall operational disruptions, it said.Posco did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

KRX:005490
Asia

HBM Partner Reports Positive Interim Results in Phase 2 Trial of Asthma Treatment

HBM Holdings' (HKG:2142) partner, Windward Bio AG, has reported positive interim results from the Phase 2 POLARIS-1 trial evaluating the company's treatment for asthma, according to a Tuesday bourse filing.The biopharmaceutical company said subjects responded well to its treatment, HBM9378/WIN378, during the trial conducted by Windward Bio, and observed no serious adverse events.HBM's partner has kicked off the Phase 3 trial and is also planning a second Phase 3 study, POLARIS-2, in the first half of next year.The company's shares were up 3% in early open-market trading in Hong Kong.

HKG:2142